

Description

- World's most comprehensive and broadly based manufacturer of health care products
- Serves the Consumer, Pharmaceutical and Medical Devices and Diagnostics markets with a focus on research-based, technology-driven products

Consistent Performance

- 27 consecutive years of earnings increases adjusted for special items
- 49 consecutive years of dividends increases (includes April 2011 dividend increase)

| | One Year ² | Five Years ² | Ten Years ² |
|--|-----------------------|-------------------------|------------------------|
| Sales | (0.5)% | 4.0% | 7.8% |
| Diluted Earnings per Share ¹ | 8.6% | 7.4% | 11.9% |
| Dividend Growth | 9.3% | 10.6% | 13.0% |
| Total Return to Shareholders | (0.6)% | 3.5% | 4.0% |

¹ As reported, GAAP


² Compounded Annual Growth Rates

Broadly Based/Exceptional Financial Strength


- Over 250 operating companies in 60 countries selling products throughout the world (approximately 50% of sales outside of U.S.)
- Sales split among Consumer, Pharmaceutical and Medical Devices and Diagnostics business segments
- More than 100 drugs marketed; 41 drugs over \$50 million; 29 drugs over \$100 million; 7 drugs over \$1 billion
- One of a few U.S. industrial companies that still commands a Triple A credit rating by both Standard & Poor's and Moody's credit rating agencies
- Generated annual free cash flow in 2010 of \$14.0 billion.

*Net Earnings \$U.S. Millions

*Note: As Reported, GAAP. Refer to the 2010 Historical Financial Review, Reconciliation of Non-GAAP Measures for an analysis of 2000-2010 Earnings.



New Products Introduced in Past 5 Years



2010 Worldwide
Sales \$61.6 Billion


Worldwide Market Leadership

- Largest Medical Device company
- 8th largest Pharmaceutical company globally
- 5th largest Biotech company globally
- Leadership Positions in Major Markets:
 - Antineoplastic Antibiotics
 - Antipsychotics (Injectables)
 - Anti - TNF
 - Baby & Kids Care
 - Blood Glucose Monitoring
 - Blood Screening & Typing
 - Breast Aesthetics
 - Disposable Contact Lenses
 - Electrophysiology diagnostics & catheters
 - Endovascular
 - Erythropoietins
 - Fluoroquinolones Antibiotics
 - Hormonal Contraceptives
 - Insulin Delivery
 - Lo-Cal Sweeteners
 - Minimally Invasive Surgery
 - Oral Rinses
 - Orthopaedics
 - Over-the-Counter Pharmaceuticals
 - Psychostimulants
 - Sanitary Protection
 - Sutures
 - Wound Care
- Approximately 70% of sales are derived from products/businesses that have a #1 or #2 global market share position

Please visit our Home Page on the Internet at <http://www.jnj.com> for requests for **Company Reports**, including the 2010 Annual Report and SEC filings. Questions regarding stock holdings and the **Dividend Reinvestment Plan**, should be directed to: Computershare Trust Company, N.A. Phone (800) 328-9033

Shareholder Return Comparison

\$100 Dollars invested December 31, 2005



This chart provides a comparison of cumulative total shareholder return for an investment in Johnson & Johnson Common Stock as of December 31, 2005 to a similar investment. Assuming dividends were reinvested, a \$100.00 investment in Johnson & Johnson would have grown to \$118.87 as of December 31, 2010. This compares to a value of \$111.99 for the S&P 500 Stock Index and \$118.55 for the S&P Pharmaceutical Index and \$99.24 for the S&P Health Care Equipment Index.

Source: Bloomberg


Strong Commitment to New Product Development

- \$6.8 billion in Research & Development spending in 2010
- Numerous external alliances and collaborations entered into annually
- Approximately 25% of products sold in 2010 introduced in last 5 years


Well Positioned for Future Growth

- Solid pipeline of new and innovative products
- U.S. demographics point to high growth in health care industry
- Broad geographic reach provides ability to rapidly introduce new products in markets around the world
- Focus on products which reduce the cost of health care
- Management based on a core set of Strategic Principles: Broadly based in human healthcare, decentralized management structure, long term focus and Credo based decision making.

2010 Sales by Geographic Area



2010 Sales by Segment



Investor Information

NYSE Symbol: JNJ

For additional information, contact:

Investor Relations Department
One Johnson & Johnson Plaza
New Brunswick, NJ 08933
Voice: (800) 950-5089
Fax: (732) 524-3867

Press releases, including earnings reports, are available via web access: <http://www.jnj.com>

Net Trade Sales

\$U.S. Billions

